CTOs on the Move

Adaptive Biotechnologies

www.adaptivebiotech.com

 
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people`s lives by learning from the wisdom of their adaptive immune systems. Adaptive`s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
David Arbo
Sr Director of Information Technology Profile
Josh Schmidt
Senior Director, Information Security Profile
Mark Adams
Chief Technical Officer Profile
Mark Adams
Chief Operating Officer Profile

Funding

Adaptive Biotechnologies raised $195M on 05/07/2015

Similar Companies

RootPath Genomics

RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.

Quad Five Materials Bio

Quad Five Materials Bio, Inc. is a Ryegate, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bridge Medicines

Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine.

Creative Biogene.Inc

Creative Biogene.Inc is a Shirley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tekmira Pharmaceuticals Corporation

Tekmira Pharmaceuticals Corporation is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.